Please login to the form below

I have forgotten my password

gantenerumab

This page shows the latest gantenerumab news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

s crenezumab and Roche/Chugai’s gantenerumab.

Latest news

Glimmer of hope for amyloid drugs in Alzheimer's?

Roche also had updated results from a previously-reported trial of its gantenerumab candidate that failed to show a benefit on cognition.
Biogen Idec claims first with Alzheimer's candidate

That view took a knock last December however when Roche announced it was halting a phase III trial of its gantenerumab candidate in prodromal Alzheimer's after an independent panel concluded
AB Science on track for phase III data in Alzheimer's this year

of patients, with a host of failed projects including most recently Roche's gantenerumab.
Double trial disappointment for Roche

The Swiss pharma company will discontinue a phase III programme investigating its anti-amyloid medicine gantenerumab in people in the early stages of Alzheimer's after an analysis of interim data. ... Roche has not given up on gantenerumab completely,
Novartis launches Alzheimer’s prevention study

One of the drugs to fail at this late stage – Lilly's solanezumab – is currently being tested in an Alzheimer's prevention study alongside Roche's dementia hope gantenerumab. ... Like many other investigational Alzheimer's treatments solanezumab and

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Latest from PMHub

Alzheimer’s disease: reviewing the immediate treatment horizon

Crenezumab, gantenerumab, and solanezumab are all involved in additional prospective longitudinal investigations – the Alzheimer’s Prevention Initiative (Phase 2), the Dominantly Inherited Alzheimer Network study (Phase 2/3), and

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Director development role to Business Director, H...: Excellent package

PRINCIPAL MEDICAL WRITER > ETL - LONDON / NEW YORK/ HOME - ME...: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Home-based Senior Project Manager – Independent Med Ed: Salary TBC

Medical Writer: Salary TBC

Global Business Development Director – Health Education: excellent commission

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Engagement Expert, Healthcare Brand Communications, London: Excellent package

Account Director – Health Policy – Global Agency: Salary TBC

Senior Account Manager, Rare Diseases – Medical Communications, ...: Excellent package

Associate Director: £75, 000-90, 000

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Senior Medical Writer: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Account Director – Healthcare Marketing – Berks: Salary TBC

Client Services Director – Medical Education Agency – North West...: Salary TBC

Account Director, Medical Education: Salary TBC

Account Manager / Account Director: Competative

Subscribe to our email news alerts

PMHub

Add my company

Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

Unlocking the potential of science and technology in the UK: Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints: What to expect from 2019...
Not another weight-loss ad: Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...